CD28 and cancer: Taken together, these T-cell and cancer-cell binding results suggest that XmAb808 sequentially engages its two targets, first by avid and high-affinity binding to B7-H3, followed by binding to CD28, to form an artificial immunologic synapse between T cells and B7-H3+ cancer cells.